The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats
Abstract
Diabetes alters microvascular function in the vascular beds of organs, including the lungs. Cardiovascular complications of pulmonary vascular affectation may be a consequence of the overactivation of the vasoconstrictive and proliferative components of the renin-angiotensin system. We previously reported that pulmonary physiology and surfactant production is improved by the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide (LIR) in a rat model of lung hypoplasia. Because we hypothesized that streptozotocin-induced diabetes rats would show deficiencies in lung function, including surfactant proteins, and develop an imbalance of the renin-angiotensin system in the lungs. This effect would in turn be prevented by long-acting agonists of the GLP-1R, such as LIR. The induction of diabetes reduced the surfactant protein A and B in the lungs and caused the vasoconstrictor component of the renin-angiotensin system to predominate, which in turn increased angiotensin II levels, and ultimately being associated with right ventricle hypertrophy. LIR restored surfactant protein levels and reversed the imbalance in the renin-angiotensin system in this type 1 diabetes mellitus rat model. Moreover, LIR provoked a strong increase in angiotensin-converting enzyme 2 expression in the lungs of both diabetic and control rats, and in the circulating angiotensin(1–7) in diabetic animals. These effects prompted complete reversion of right ventricle hypertrophy. The consequences of LIR administration were independent of glycemic control and of glucocorticoids, and they involved NK2 homeobox 1 signaling. This study demonstrates by first time that GLP-1R agonists, such as LIR, might improve the cardiopulmonary complications associated with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
RetractedA role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924
Physiology of Local Renin-Angiotensin Systems
Paul, M., Poyan Mehr, A., & Kreutz, R. (2006) · Physiological Reviews · doi:10.1152/physrev.00036.2005 · Cited by 1,739
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Heller, R. S., Kieffer, T. J., & Habener, J. F. (1997) · Diabetes · doi:10.2337/diab.46.5.785 · Cited by 179
Effect of GLP-1 on lipid metabolism in human adipocytes
Villanueva-Peñacarrillo, M. L., Márquez, L., González, N., Díaz-Miguel*, M., & Valverde, I. (2001) · Hormone and Metabolic Research · doi:10.1055/s-2001-12428 · Cited by 113
Romaní-Pérez, M., Outeiriño-Iglesias, V., Gil-Lozano, M., González-Matías, L. C., Mallo, F., & Vigo, E. (2013) · Endocrinology · doi:10.1210/en.2012-1786 · Cited by 51
Self-citation
Cited by
Huang, I., Lim, M. A., & Pranata, R. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.04.018 · Cited by 933
Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations
Singh, A. K., Gupta, R., Ghosh, A., & Misra, A. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.04.004 · Cited by 893
COVID-19 pandemic, coronaviruses, and diabetes mellitus
Muniyappa, R., & Gubbi, S. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00124.2020 · Cited by 869
Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications
Drucker, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa011 · Cited by 399
Obesity ‑ a risk factor for increased COVID‑19 prevalence, severity and lethality (Review)
Petrakis, D., Margină, D., Tsarouhas, K., Tekos, F., Stan, M., Nikitovic, D., Kouretas, D., Spandidos, D., & Tsatsakis, A. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11127 · Cited by 388
Metadata
- Authors
- Romaní-Pérez, M., Outeiriño-Iglesias, V., Moya, C. M., Santisteban, P., González-Matías, L. C., Vigo, E., & Mallo, F.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2015-07-21
- Volume
- 156
- Issue
- 10
- Pages
- 3559-3569
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1831655817
- Cited by
- 178
- References
- 8
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.